A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
about
Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's DiseaseSerious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Hematological disorders in patients with systemic lupus erythematosus.Pulmonary Sarcoidosis That Developed During the Treatment of a Patient With Crohn Disease by Using InfliximabRisk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.What causes alopecia areata?Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysCytokine modulators in the treatment of sarcoidosis.Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus.Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel.Occult pulmonary mucosa-associated lymphoid tissue lymphoma presenting as catastrophic antiphospholipid antibody syndrome.Developments in the clinical understanding of lupusClinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Rituximab therapy in lupus nephritis: current clinical evidence.Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders.Update on the role of rituximab in kidney diseases and transplant.Biologic agents in experimental autoimmune uveitis.B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.B-cell-targeted therapy in adult glomerulonephritis.Osseous sarcoidosis: a case series.Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.Emerging Therapies in Antiphospholipid Syndrome.Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Transmembrane TNF-α Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-β: Therapeutic Implications.Improvement of Anti-TNF-α Antibody-Induced Palmoplantar Pustular Psoriasis Using a 308-nm Excimer Light.IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis.Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment.Abdominal pain, flank pain, blurry vision, and lower extremity weakness in a 16-year-old female.Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).Networking in Europe for special centres of excellence for autoimmune diseases.
P2860
Q26772331-E4FC0D04-3F4C-4452-9E17-57CB754EB60DQ30731527-E59FD5F6-9D11-403A-A1FE-B3FECC214E2FQ33407247-8541DF6F-48A7-42A9-BBEC-8B0485CA92CFQ33411323-D994DA3E-7E09-4F8D-A4D2-265DC1182095Q33661114-C36C3FD6-CC37-45F4-AC22-27DB4996F2DDQ33757203-2CB15704-151C-43FE-9568-D6D848B2F0D7Q33889367-9D550599-2C0E-4EB0-A2C2-DFEF4AD671C8Q33915940-C2078EEC-CE9D-41BB-A060-7F8D24648782Q33944243-BEA9C99F-679E-4FD3-BC6C-DFFA5B740E57Q34190083-33AF31FF-30F1-45E9-A24D-314C0FFC578CQ35031692-C8D634F6-DB25-4F0E-A9BB-F8DF84732483Q35617617-6A38EF35-99FF-4D77-AF8D-70654858DFA4Q35621012-ABC15D0F-B064-4168-AF4A-4E57D56F501DQ36612326-53A2F0AF-CCCF-444E-8F6C-9A80C655CAE9Q36766536-BC717D44-EE14-4631-8CC0-2780BAC44F6DQ37269605-C2D09BAD-2559-47F0-960E-E3465D2B2CDCQ37453947-C2B2F7BD-E0B4-43BD-880E-1B666B6F8296Q37650221-A1434774-F3D7-43D7-9F91-89DB54117083Q37737138-7AB25A7C-31E3-407B-AE1E-1A09F6154BA0Q37754686-E9058C1A-DF13-4C43-A120-1D85E6376D4DQ37970443-7384CA1A-FF35-47E5-8FF8-5DACD42DDEDEQ38089645-64FA21EC-5212-4393-8BB4-9677F2571E7EQ38097129-EBCFC09D-91C8-4BA3-BCBF-8914673113D5Q38149856-E4571B90-EA14-4F81-9932-F65E269DC667Q38159787-24FDB9EA-6FD6-4976-BD05-1503651C985EQ38264262-AC27EEBE-764F-4870-920D-EAD1CA95C32DQ38365468-0041FAA5-8E4C-4F65-8317-BDFF271FF7B3Q38782057-9EDAFA1C-87EB-488E-AF3E-BDEC63A054D5Q38826765-BDE00449-E475-4AB0-9D60-891D28C76BA6Q39100810-237DDB76-3D22-454A-AC33-113474720A96Q40146734-43FEE338-31A0-42F1-846C-FBBD9E491BB8Q41818578-F8C253B5-89F8-4CC9-9C42-0E3B7A241878Q43693855-D6F673CB-F764-42F9-9196-DB29B5E524CCQ45012824-E4FC8E44-1E1C-40CF-A1F0-A5BEF040010EQ45773011-A01D42C5-7D2F-4CF5-9270-8603FA9F3C38Q47102392-50E89995-E641-4653-B59A-54198D63B80AQ51144375-2BE50915-1D06-4A0D-A0E7-87C32B4C072CQ51146578-6FEA26F0-A3F0-40F2-B804-A1FEFD533580Q51201612-D066E0EC-BF3B-4001-BB83-EF9757712673Q53189383-A85921D3-D605-44C0-A3CF-833F4C50A948
P2860
A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A systematic review of the off ...... systemic autoimmune diseases.
@en
A systematic review of the off ...... systemic autoimmune diseases.
@nl
type
label
A systematic review of the off ...... systemic autoimmune diseases.
@en
A systematic review of the off ...... systemic autoimmune diseases.
@nl
prefLabel
A systematic review of the off ...... systemic autoimmune diseases.
@en
A systematic review of the off ...... systemic autoimmune diseases.
@nl
P2093
P1433
P1476
A systematic review of the off ...... systemic autoimmune diseases.
@en
P2093
BIOGEAS STUDY Group
María-José Soto
Pilar Brito-Zerón
Sandra Muñoz
P304
P356
10.1097/MD.0B013E318190F170
P407
P577
2008-11-01T00:00:00Z